Filter Results:
(1,243)
Show Results For
- All HBS Web
(1,243)
- People (5)
- News (171)
- Research (927)
- Events (6)
- Multimedia (12)
- Faculty Publications (755)
Show Results For
- All HBS Web
(1,243)
- People (5)
- News (171)
- Research (927)
- Events (6)
- Multimedia (12)
- Faculty Publications (755)
- January 2009 (Revised July 2009)
- Case
Targanta Therapeutics: Hitting a Moving Target
By: Arthur A. Daemmrich
This case explores regulatory, product testing, and business strategy at Targanta Therapeutics, a biotech company preparing its first new drug application to the FDA. In October 2007, Mark Leuchtenberger, president and CEO of Targanta—which has just held a successful... View Details
Keywords: Decision Choices and Conditions; Entrepreneurship; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Product Development; Business and Government Relations; Business Strategy; Pharmaceutical Industry; Pharmaceutical Industry
Daemmrich, Arthur A. "Targanta Therapeutics: Hitting a Moving Target." Harvard Business School Case 709-002, January 2009. (Revised July 2009.)
- March 2005 (Revised August 2005)
- Case
Procurement at Betapharm Corp. (A)
Presents a move by Betapharm to centralize procurement and e-sourcing and the many control and incentive issues that arose subsequently. View Details
Keywords: Motivation and Incentives; Governance Controls; Supply Chain Management; Pharmaceutical Industry; Pharmaceutical Industry
Kulp, Susan L., and Taylor Randall. "Procurement at Betapharm Corp. (A)." Harvard Business School Case 105-030, March 2005. (Revised August 2005.)
- June 2003 (Revised March 2008)
- Case
Schering-Plough and Genome Therapeutics: Discovering an Asthma Gene
By: Regina E. Herzlinger and Marc Aquino
Personalized medicine requires the identification of mutated genes. Schering-Plough's search for the one related to asthma requires finding families with the disease. Examines the industry that helps conduct such research, including contract research organizations. View Details
Keywords: Health Disorders; Research and Development; Genetics; Pharmaceutical Industry; Pharmaceutical Industry
Herzlinger, Regina E., and Marc Aquino. "Schering-Plough and Genome Therapeutics: Discovering an Asthma Gene." Harvard Business School Case 303-044, June 2003. (Revised March 2008.)
- February 1997 (Revised June 1999)
- Teaching Note
Massachusetts General Hospital: CABG Surgery (A) TN
Teaching Note for (9-696-015). View Details
- November 1995 (Revised March 2004)
- Case
Massachusetts General Hospital: CABG Surgery (A)
By: Steven C. Wheelwright and James Weber
A cross-functional team at Massachusetts General Hospital tries to reengineer the service delivery process (the "care path") for heart bypass surgery (CABG) in order to shorten hospital stays (and lower costs) while maintaining/enhancing the quality of care provided. View Details
Keywords: Health Care and Treatment; Medical Specialties; Business Processes; Mission and Purpose; Product Positioning; Product Marketing; Management Practices and Processes; Customer Satisfaction; Service Delivery; Service Operations; Fair Value Accounting; Ethics; Pharmaceutical Industry; Pharmaceutical Industry; Massachusetts
Wheelwright, Steven C., and James Weber. "Massachusetts General Hospital: CABG Surgery (A)." Harvard Business School Case 696-015, November 1995. (Revised March 2004.)
- September 1997 (Revised October 1997)
- Case
Bayer AG (A)
By: John A. Quelch
Bayer's senior executives convene in Germany to consider submitting a $1 billion bid that would recover the Bayer brand name and trademark cross in North America, both of which were confiscated by the U.S. government after World War I. The group also sets out to assess... View Details
Keywords: Management Teams; Brands and Branding; War; Communication; Trademarks; Acquisition; Government and Politics; Pharmaceutical Industry; Pharmaceutical Industry; Germany; North America; United States
Quelch, John A., and Robin Root. "Bayer AG (A)." Harvard Business School Case 598-031, September 1997. (Revised October 1997.)
- November 1991 (Revised December 1991)
- Case
SmithKline Beecham Animal Health
By: Ray A. Goldberg
Goldberg, Ray A. "SmithKline Beecham Animal Health." Harvard Business School Case 592-053, November 1991. (Revised December 1991.)
- 14 Dec 2010
- First Look
First Look: Dec. 14
addresses a decision to replace salesmen netbook PCs with iPhones, including converting the company's sales and customer applications to the iPhone platform. Purchase this case:http://cb.hbsp.harvard.edu/cb/product/911413-PDF-ENG Hikma View Details
Keywords: Sean Silverthorne
- 18 Aug 2017
- Op-Ed
Op-Ed: Courageous Leader Triggers a Moral Revolt of CEOs Against Trump
actions was not without risk for the CEOs and their companies” While many CEOs prefer to stay under the radar and avoid public scrutiny, Ken Frazier led the way with his example. As the chair of PhRMA, the pharmaceutical manufacturers... View Details
Keywords: by Bill George
- 20 May 2013
- Op-Ed
Making America an Industrial Powerhouse Again
talent pool in the US biomedical field that is second to none. And the only way to get that talent is for companies-both domestic and foreign-to do their R&D here. That's why pharmaceutical and biotechnology companies from around the... View Details
- 16 Oct 2007
- First Look
First Look: October 16, 2007
this case: http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=508036 Michael Fernandes at Nicholas Piramal Harvard Business School Case 408-001 Michael Fernandes, the Director of Custom Manufacturing Operations at the View Details
Keywords: Sean Silverthorne
- 15 Feb 2000
- Research & Ideas
The Right Connections
pharmaceutical companies — what the authors call downstream social capital — had a direct impact on the size of the startup's IPO. "Downstream social capital was essential in attracting the interest of a top investment bank and... View Details
Keywords: by Judith A. Ross
- 26 Apr 2023
- Cold Call Podcast
How Martine Rothblatt Started a Company to Save Her Daughter
- Research Summary
Overview
I am interested in the individual experience of learning in organizational settings, particularly how employees learn to learn from the challenging work they do.
I am currently researching the role of reflection for raising awareness of learning opportunities that... View Details
- January 2023
- Teaching Note
The Opioid Settlement and Executive Pay at AmerisourceBergen
By: Suraj Srinivasan and Li-Kuan Ni
Teaching Note for HBS Case No 122-014. In 2020, AmerisourceBergen Corporation, a Fortune 50 company in the drug distribution industry, agreed to settle thousands of lawsuits filed nationwide against the company for its opioid distribution practices that critics alleged... View Details
Keywords: Opioids; Shareholder Activism; Investment Activism; Corporate Accountability; Corporate Governance; Governance Compliance; Governance Controls; Executive Compensation; Risk Management; Corporate Social Responsibility and Impact; Business and Shareholder Relations; Business and Stakeholder Relations; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States; West Virginia; Tennessee; Ohio; Pennsylvania
- Article
Internal Deadlines, Drug Approvals, and Safety Problems
By: Lauren Cohen, Umit Gurun and Danielle Li
Absent explicit quotas, incentives, reporting, or fiscal year-end motives, drug approvals around the world surge in December, at month-ends, and before respective major national holidays. Drugs approved before these informal deadlines are associated with significantly... View Details
Keywords: Health; Economics; Government and Politics; Innovation and Invention; Research; Science; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
Cohen, Lauren, Umit Gurun, and Danielle Li. "Internal Deadlines, Drug Approvals, and Safety Problems." American Economic Review: Insights 3, no. 1 (March 2021): 67–82.
- February 1999
- Teaching Note
Wegmans Food Markets: Diabetes Counseling TN
By: David E. Bell
Teaching Note for (9-599-057). View Details
- 19 Sep 2012
- Research & Ideas
Funding Innovation: Is Your Firm Doing it Wrong?
the scale and resources of the corporate lab with some of the intensity and urgency associated with the venture capital model, you have something that can be very, very strong," Lerner says. The book describes how, in 2008, the View Details
Keywords: by Carmen Nobel
- 03 Aug 2016
- What Do You Think?
How Can We Hold the “Leadership Industry” Accountable?
these leadership industry issues varied. Pradip commented: “In a competitive industry there are many who want everyone to ‘buy in’ (to) their half baked research as ‘new truth.’” He called for a “rigorous research methodology” like what is used to test View Details
- 08 Jul 2021
- Blog Post
Managing Sustainable Advantage with Key ESG Co-Founders, Anne-Marie Schoonbeek and Heleen van Poecke
internship and then later back to McKinsey after graduation, where she focused on both large-cap and startups in the pharmaceuticals and biotech space. “For me, this was a way of making an impact,” said Schoonbeek. van Poecke began her... View Details